Selected publications from the team
- Decorsière A., Mueller H., van Breugel PC., Abdul F., Gerossier L., Beran RK., Livingston CM., Niu C., Fletcher SP., Hantz O., Strubin M. (2016). Hepatitis B virus X protein identifies the smc5/6 complex as a host restriction factor. Nature, 531, 386-389.
- Boudra MT., Bolin C., Chiker S., Fouquin A., Zaremba T., Vaslin L., Biard D., Cordelières FP., Mégnin-Chanet F., Favaudon V., Fernet M., Pennaneach V. and Hall J. (2015). PARP-2 depletion results in lower radiation cell survival but cell line-specific differences in poly(ADP-ribose) levels. Cell. Mol. Life Sci., 72, 1585-1597.
- Chapellier M., Bachelard-Cascales E., Schmidt X., Clément F., Treilleux I., Delay E., Jammot A., Ménétrier-Caux C., Pochon G., Besançon R., Voeltzel T., Caron de Fromentel C., Caux C., Blay JY., Iggo R. and Maguer-Satta V. (2015). Disequilibrium of BMP2 Levels in the Breast Stem Cell Niche Launches Epithelial Transformation by Overamplifying BMPR1B Cell Response. Stem Cell Reports, 4, 239-254.
- Paul S., Rochereau N., Martinez P., Stratmann T., Delputte C., Delprat C., Poland GA. (2015). Answering the call for educating the new generation of vaccinologists – A new european erasmus(+) Joint Master Degree in vaccinology. Vaccine, 33, 6135-6.
- Petit M-A., Berthillon P., Pradat P., Arnaud C., Bordes I., Virlogeux V., Maynard M., Bailly F., Zoulim F., Chemin I. and Trépo C. (2015). Anti-E1E2 antibodies do predict response to triple therapy in treatment-experienced Hepatitis C Virus-cirrhosis cases. Clin Res Hepatol Gastroenterol., 39, 699-704.
- Rivière L., Gerossier L., Ducroux A., Dion S., Deng Q., Michel M-L., Buendia M-A., Hantz O. and Neuveut C. (2015). HBx relieves chromatin-mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase. J. Hepatol., 63, 1093-1102.
- Villiers MB., Cortay JC., Cortès S., Bloquel B., Brichler S., Brakha C., Kay A., Falah N., Zoulim F., Marquette C., Marche PN. and Dény P. (2015). Protein/peptide arrays to detect anti-Delta genotype 1, 6, 8 specific antibodies among Hepatitis D Virus infected patients, by surface plasmon resonance imaging. J. Clin. Microbiol., 53, 1164-1171.
- Delprat C and Aricò M. (2014). Blood spotlight on Langerhans Cell Histiocytosis. Blood, 124, 867-72.
- Guillot C., Favaudon V., Herceg Z., Sagne C., Sauvaigo S., Merle P., Hall J. and Chemin I.(2014). PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models. BMC Cancer, 14, 603.
- Dupinay T., Gheit T., Roques P., Cova L., Chevallier-Queyron P., Tasahsu SI., Grand RL., Simon F., Cordier G., Wakrim L., Benjelloun S., Trépo C. and Chemin I. (2013). Discovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from Mauritius Island. Hepatology 58, 1610-1620.
- Olsson Åkefeldt S., Ismail MB., Valentin H., Aricò M., Henter JI. and Delprat C. (2013). Targeting BCL2 Family in Human Myeloid Dendritic Cells: A Challenge to Cure Diseases with Chronic Inflammations Associated with Bone Loss. Clin. Dev. Immunol., Article ID 701305.
- Pez F., Lopez A., Kim M., Wands JR., Caron de Fromentel C. and Merle P. (2013). Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. J. Hepatol. 59, 1107-1117.
- Gouas DA., Villar S., Ortiz-Cuaran S., Legros P., Ferro G., Kirk GD., Lesi OA., Mendy M., Bah E., Friesen MD., Groopman J., Chemin I. and Hainaut P. (2012). TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia. Carcinogenesis 33, 1219-24.
- Studach LL., Menne S., Cairo S., Buendia MA., Hullinger RL., Lefrançois L., Merle P. and Andrisani OM. (2012). A subset of Suz12/PRC2 target genes is activated during HBV replication and liver carcinogenesis associated with hepatitis B virus X protein. Hepatology 56, 1240-51.